Sarepta疗法 SRPT 深 沪
等待开盘 04-01 09:30:00 美东时间
21.76
+1.280
+6.25%
华盛通- 最 高22.105
- 今 开20.72
- 成交量 229.87万股
- 最 低 20.72
- 昨 收 20.48
- 总市值 22.85亿
- 52周最高 64.80
- 市盈率 静 --
- 换手率 2.19%
- 52周最低 10.415
- 委 比 74.58%
- 总股本 1.05亿
- 历史最高 181.83
- 量 比 0.33
- 振 幅 6.76%
- 历史最低 0.433
- 每 手 1
- 风险率 12.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus
U.S. stocks ended Friday broadly lower, with selling pressure intensifying across sectors as investors weighed persistent geopolitical risks tied to tensions in the Middle East. The tech-focused Nasda...
03-29 21:05
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, heavily weighted toward tech stocks, officially entered correction territory.
03-28 01:09
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
03-26 23:25
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop March 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Equitable Holdings, Robinhood Markets and Wingstop on Thursday. HIGHLIGHTS * Equitable Holdi
03-26 15:38
美股牛股 | SpaceX冲刺上市点燃情绪！太空概念Sidus大涨18%，Firefly涨超16%；ARM官宣下场造芯片
SpaceX冲刺上市点燃情绪！太空概念Sidus大涨18%，Firefly涨超16%；芯片设计巨头ARM单日飙涨16%，官宣亲自下场造芯片>>
03-26 18:52
Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta stock jumps after siRNA data show protein reduction, while analysts remain split on outlook and valuation.
03-25 23:17
Sarepta gains on data for muscular dystrophy therapies
Sarepta Therapeutics (SRPT) added ~25% in the morning hours on Wednesday after the company posted initial data from Phase 1/2 trials for its experimental drugs targeted at two rare forms of muscular d...
03-25 21:49
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - Wall Street's main indexes were set to open higher on W
03-25 21:29
Sarepta Reports Early siRNA Trial Results With Strong Muscle Targeting And Favorable Safety Profile
In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1Company to host investor call on March 25, 2026, at 8:30 a.m.
03-25 20:07
